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QuinolinesAbstract A series of 3-substituted 6-methoxy-1H-pyrazolo [3,4-b]quinoline derivatives was synthe-
sized by treating 6-methoxy-1H-pyrazolo[3,4-b]quinolin-3-amine (6) with different acid anhydrides
including succinic anhydride, maleic anhydride and phthalic anhydride. Also, a series of 3-hetero
aryl-2-chloro-6-methoxyquinolines was prepared through 1,3-dipolar cycloaddition of different
bi-nucleophiles including hydrazine hydrate, hydroxylamine hydrochloride, thiourea, guanidine
hydrochloride, urea and metformin hydrochloride to the chalcone derivative 3-(2-chloro-6-methoxy-
quinolin-3-yl)-1-(4-methoxyphenyl)prop-2-en-1-one. Structural identifications of all products were
reported and the new compounds were screened for their in vitro antimicrobial activity against Strep-
tococcus pneumonia and Bacillus subtilis as examples for Gram-positive bacteria, Pseudomonas aerug-
inosa and Escherichia coli as examples for Gram-negative bacteria, and Aspergillus fumigatus,
Syncephalastrum racemosum, Geotriucum candidum and Candida albicans as representative examples
of fungi. The majority of tested compounds showed moderate activities against a wide range of the
selected organisms. Among the tested compounds, pyrimidine derivatives 16 and 17 showed the high-
est antimicrobial activity against gram-positive strains while the highest activity against E. coli as
example for Gram-negative strains was observed in the case of 11 and 17. Compounds 14 and 17 were
found to be extremely potent against three of the selected fungal strains.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
1H-pyrazolo[3,4-b]quinolines revealed a wide range of biolog-
ical activities for example as antimicrobial agents1,2 antiviral,3
and as amebicidal.4 There are two main procedures for the
synthesis of 1H-pyrazolo[3,4-b]quinolines (Fig. 1). The first
one starts with a preformed pyrazole, then constructing the
Figure 1 Reported methods for synthesis of 1H-pyrazolo[3,4-b]
quinolines.
264 K.M. El-Gamal et al.quinoline ring during the reaction sequence.5,6 This can be
achieved by either condensation of the appropriate ortho-
amino aryl ketones or aldehydes with 1H-pyrazol-5(4H)-
ones7 or by cyclization of anilines with 4-arylidenepyrazolin-
5-ones.8 The second procedure starts with a prebuilt quinoline
followed by construction of a pyrazole ring during the
sequence. This procedure includes reaction of 2-chloro-3-
cyanoquinolines with hydrazine giving 3-amino-1H-pyrazolo
[3,4-b]quinolines.9,10 The present work showed synthesis of
three 6-methoxy-1H-pyrazolo[3,4-b]quinoline derivatives fol-
lowing the latter category of reaction sequence in continuation
with our recent work 11 on antimicrobial quinolines. Reaction
of succinic, maleic, or phthalic anhydrides with arylamines
yields N-arylsuccinimide, N-arylmaleimide and N-
arylphthalimide respectively.12 Among available methodolo-
gies for creation of CAC bond, Claisen–Schmidt reaction is
the most powerful one for joining two aryl moieties.13 In the
current work, 3-(2-chloro-6-methoxyquinolin-3-yl)-1-(4-meth-
oxyphenyl)prop-2-en-1-one, belonging to a,b-unsaturated
ketones, was prepared following Claisen–Schmidt condensa-
tion reaction. a,b-Unsaturated ketones (Chalcones) are well
known intermediates for synthesis of various heterocycles14
like pyrimidine-2(1H)-thione, pyrimidine,15 pyrazole,16 isoxa-
zole17 and pyrimidin-2(1H)-one. In addition, literature survey
revealed that many pyrazoline derivatives were reported to
have antibacterial effects.18 Pyrimidines also are of remarkable
pharmaceutical importance as antitubercular.19
Some of the newly synthesized quinolines (Fig. 2) like Beda-
quiline (1) found extraordinary active against Mycobacterium
tuberculosis.20 Laquinimod (2) is an investigational quinoline
derivative for treatment of multiple sclerosis (MS).21 Glaxo-
SmithKline 299423 (3) is also a potent quinoline derivativeFigure 2 Chemical structures of some potagainst antibiotic-resistant strains as Staphylococcus aureus
and Escherichia coli.22
In view of the above mentioned facts and as a continuation
of the global interest in the development of new antimicrobial
agents, the main aim of this work is to synthesize a new set of
antibacterial agents belonging to quinoline scaffold that can-
not be recognized by bacterial resistant machineries. In this
study, Glaxo-SmithKline 299423 (3) was used as lead com-
pound with some structural modification to obtain active
antimicrobial compounds.
2. Results and discussion
2.1. Chemistry
The new 3-Substituted-6-Methoxy-1H-pyrazolo[3,4-b]quino-
line derivatives were prepared through reaction of 6-
methoxy-1H-pyrazolo[3,4-b]quinolin-3-amine with acid anhy-
drides. The yields obtained by this method were 60% or more.
Structure confirmation of pyrazolo[3,4-b]quinoline derivatives
7–9 was performed based on their spectral data (IR, 1H NMR,
and MS). The IR spectra of these compounds showed the char-
acteristic C‚O amide absorption bands of amide at the range
of 1660–1670 cm1 while NH stretching bands were observed
in the range of 3260–3270 cm1. 1H NMR spectra of these
amides are found characterized by the presence of D2O
exchangeable singlet of the NH proton at d 12.8–13.8 in addi-
tion to another singlet of three protons of methoxy group at
3.8 ppm. In the present study, chalcone 10 was prepared
through the reaction of compound 4 with p-
methoxyacetophenone in the presence of alcoholic NaOH.
The reaction occurred by ratio (1:1) to form chalcone which
crystallized from ethanol, the structure of compound 10 was
established on the basis of its elemental and spectral data.
The IR spectrum of compound 10 was characterized by a
strong absorption band of C‚O which appeared at low
absorption value because of extended conjugation with the
double bond. The absolute geometry of the a,b-unsaturated
carbonyl linker was assigned to be in trans form based on
the coupling constant of alkene protons. In more details, the
1H NMR spectrum of chalcone 10 showed two doublets, each
equivalent to one proton. Both have the same coupling con-
stant value of 15.0 Hz, which confirms the E-configuration.
Additionally, the 1H NMR spectrum of compound 10 dis-
played two more doublets, each of two protons with a coupling
constant value of 9.0 Hz which is attributed to the p-
disubstituted phenyl ring. Fig. 3 provides the proposed mech-
anism for the formation of compound 10. In this work, seven
different 1,3-dipolar cyclo-addition reactions have been
achieved. Namely, chalcone 10 was allowed to react withent antimicrobial quinoline derivatives.
Figure 3 Proposed mechanism for formation of compound 10.
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guanidine hydrochloride, urea, biguanide metformin
hydrochloride, and S-methyisothiourea. In general, all reac-
tions proceeded smoothly and final products were obtained
in relatively good yields as detailed in the experimental part.
Scheme 1 shows the synthetic pathway of the target com-
pounds 7–9 through reaction of 6-Methoxy-1H-pyrazolo[3,4-
b]quinoline-3-amine (6) with three different acid anhydrides.Scheme 1 Synthetic protocol of compounds 7–9.Structures of these amides were confirmed based on spectral
data and elemental analyses. The IR spectra of these com-
pounds showed the characteristic C‚O stretching bands at
the range of 1666–1669 cm1. In addition, the 1H NMR spec-
tra of the same derivatives showed singlet signals correspond-
ing to NH protons at d 12.8–13.8 ppm. Structures of the 3-
heteroaryl-2-chloro-6-methoxyquinolines derivatives 11–17
(Scheme 2) were confirmed by the disappearance of the two
doublets with high coupling constant of the alkene protons
in the starting chalcone at d 8.1 and 7.9 that confirm the
cyclization reactions. In addition, other additional characteris-
tic new signals for each new derivative as shown in detail in the
experimental part. In the 1H NMR spectra of compounds 11
and 12, the CH2ACH fragments in pyrazoline and isoxazoline
rings respectively showed the characteristic pattern of ABX
system. CH2ACH fragment of pyrazoline ring in compound
11 showed three doublet of doublets at chemical shifts 5.1,
3.6 and 2.9 while that of isoxazoinle in compound 12 showed
these doublet of doublets at d 6.0, 4.0 and 2.9.
2.2. Biological evaluation
All of the newly synthesized derivatives were evaluated as
antimicrobial against two Gram-positive and two Gram-
negative bacteria as well as many fungal strains. All of the test
compounds showed promising activities as antimicrobial. Agar
diffusion method23,24 was carried out to determine the in vitro
antibacterial activity of the newly synthesized derivatives. In
this work, two Gram-positive organisms (Streptococcus pneu-
moniae, Bacillus subtilis) and two Gram-negative organisms
(Pseudomonas aeruginosa, and E. coli) were used to investigate
the antibacterial activity.
3. Experimental
3.1. General
All melting points were determined by open capillary using
Gallenkamp melting point apparatus and are uncorrected.
The IR spectra were recorded on potassium bromide disks
on a Pye Unicam SP 3300 spectrophotometer. 1H NMR spec-
tra were recorded on Gemini 300 MHz using TMS as an inter-
Scheme 2 Synthetic protocol of compounds 10–17.
266 K.M. El-Gamal et al.nal standard. All chemical shifts are reported in ppm downfield
from TMS. Mass spectra were recorded on a Shimadzu
GCMS-QP 1000 EX mass spectrometer operating at 70 eV.
Elemental analyses were carried out at the Regional Center
for Mycology and Biotechnology, Al-Azhar University, Cairo,
Egypt. Progress of the reactions was monitored by TLC sheets
precoated with UV fluorescent silica gel Merck 60 F254 plates
and were visualized using UV lamp and n-hexane: ethyl acetate
9: 1 as mobile phase. Starting materials were purchased from
Aldrich Chemical Company and used without further purifica-
tion. Compounds 4 and 5 were prepared according to reported
procedures.25,26 6-Methoxy-1H-pyrazolo[3,4-b]quinoline-3-
amine (6) was prepared according to Jorda et al.27 procedure.
For synthesis of the new derivatives, Schemes 1 and 2 were
adopted.3.2. 1-(6-Methoxy-1H-pyrazolo[3,4-b]quinolin-3-yl)
pyrrolidine-2,5-dione (7)
A mixture of compound 6 (2.14 g, 0.01 mol) and Succinic
anhydride (1 g, 0.01 mol) were refluxed in acetic acid (50 ml)
for 4 h, the reaction mixture was filtered off while hot and
the solvent was evaporated, the solid separated was filtered
and recrystallized from ethanol. Yield: 60%; m.p. 240 C. IR
(KBr) cm1: 3265 (NAH), 3077 (CAH aromatic), 2940
(CAH aliphatic), 1669 (C‚O). 1H NMR (DMSO-d6) d ppm:
12.8 (s, 1H, NH), 8.9 (s, 1H, quinoline-H4), 7.8 (d, 1H,
J = 9.0 Hz, quinoline-H8), 7.5 (d, 1H, J = 9.0 Hz,
quinoline-H7), 7.43 (s, 1H, quinoline-H5), 3.89 (s, 3H,
OCH3), 2.69 (s, 4H, 2CH2). MS (m/z): 296 (C15H12N4O3,
65%, M+), 281 (C14H9N4O3, 4%), 267 (C14H11N4O2,
Synthesis, characterization and antimicrobial evaluation of some novel quinoline derivatives 26715.8%), 214 (C11H10N4O, 100%), 198 (C11H8N3O, 6.5%).
Anal. Calc. for: (C15H12N4O3) (M.W. = 296): C, 60.81; H,
4.08; N, 18.91; Found: C, 60.82; H, 4.08; N, 18.92%.
3.3. 1-(6-Methoxy-1H-pyrazolo[3,4-b]quinolin-3-yl)-1H-
pyrrole-2,5-dione (8)
A mixture of compound 6 (2.14 g, .01 mol) and maleic anhy-
dride (0.98 g, 0.01 mole) was refluxed in acetic acid (50 ml)
for 4 h, the reaction mixture was filtered off while hot and
the solvent was evaporated, the solid separated was filtered
and recrystallized from ethanol to afford the titled compound
as a dark red solid. Yield: 65%; m.p. 265 C. IR (KBr) cm1:
3271 (NAH), 3051 (CAH aromatic), 2970 (CAH aliphatic),
1666 (C‚O). 1H NMR (DMSO-d6) d ppm: 13.2 (s, 1H,
NH), 8.7 (s, 1H, quinoline-H4), 8.3 (s, 2H, pyrrole-Hs), 7.7
(d, 1H, J = 9.0 Hz, quinoline-H8), 7.4 (d, 1H, J = 9.0 Hz,
quinoline-H7), 7.3 (s, 1H, quinoline-H5), 3.88 (s, 3H,
OCH3). Anal. Calc. for: (C15H10N4O3) (M.W. = 294): C,
61.22; H, 3.43; N, 19.04; Found: C, 61.24; H, 3.44; N, 19.05%.
3.4. 2-(6-Methoxy-1H-pyrazolo[3,4-b]quinolin-3-yl)
isoindoline-1,3-dione (9)
A mixture of compound 6 (2.14 g, .01 mol) and phthalic anhy-
dride (1.48 g, .01 mol) was refluxed in acetic acid (50 ml) for
4 h, the reaction mixture was filtered off while hot and the sol-
vent was removed under reduced pressure, the solid separated
was filtered and recrystallized from ethanol to afford a brown
solid. Yield: 70%; m.p. 290 C. IR (KBr) cm1: 3261 (NAH),
3071 (CAH aromatic), 2900 (CAH aliphatic), 1666 (C‚O). 1H
NMR (DMSO-d6) d ppm: 13.8 (s, 1H, NH, D2O-
exchangeable), 8.7 (s, 1H, quinoline-H4), 8.1–7.9 (m, 5H, Ar
H’s), 7.5 (d, 1H, J = 9.0 Hz, quinoline-H7), 7.4 (s, 1H,
quinoline-H5), 3.88 (s, 3H, OCH3). MS (m/z): 344
(C19H12N4O3, 100%, M
+), 329 (C18H9N4O3, 36%), 301
(C18H13N4O, 55.9%), 183 (C10H5N3O, 5%). Anal. Calc. for:
(C19H12N4O3) (M.W. = 344): C, 66.28; H, 3.51; N, 16.27;
Found: C, 66.30; H, 3.53; N, 16.28%.
3.5. 3-(2-Chloro-6-methoxyquinolin-3-yl)-1-(4-methoxyphenyl)
prop-2-en-1-one (10)
To a stirred and ice-cooled aqueous solution of sodium
hydroxide (10 mmole, 50% w/w) and absolute ethanol
(12.5 ml), 4-methoxyacetophenone (1.5 g, 10 mmole) was
added followed by 2-chloro-6-methoxyquinoline-3-carbalde
hyde (4) (2.2 g, 1 mmole). The reaction mixture was vigorously
stirred for 3 h while the temperature was maintained below
25 C till the reaction mixture became thick. The reaction mix-
ture was left in the refrigerator overnight. The formed precip-
itate was filtered off under vacuum and washed with copious
amount of water until the filtrates became neutral to litmus
paper, washed with ice-cold ethanol (20 ml), and finally recrys-
tallized from ethanol to afford compound 10 as a yellowish
white solid. Yield: 90%; m.p. 130 C. IR (KBr) cm1: 3050
(CH aromatic), 2950 (CH aliphatic), 1655 (C‚O). 1H NMR
(DMSO-d6) d ppm: 9.12 (s, 1H, quinoline-H4), 8.2 (d, 2H,
J = 9.0 Hz, phenyl-H2,H6 protons), 8.1 (d, 1H, J = 15.0 Hz,
CH alkene b proton), 7.9 (d, 1H, J = 15.0 Hz, CH alkene a
proton), 7.8 (d, 1H, J = 9.0 Hz, quinoline-H8), 7.5 (d, 1H,quinoline-H7, J = 9.0 Hz), 7.4 (s, 1H, quinoline-H5), 7.1 (d,
2H, J = 9.0 Hz, phenyl-H3, H5 protons), 3.9 (s, 3H,
quinoline-OCH3), 3.8 (s, 3H, phenyl-OCH3). MS (m/z): 355
(C20H16ClNO3, 1.7%, M+ 2), 353 (C20H16ClNO3, 5%,
M+), 318 (C20H16NO3, 78%), 303 (C19H13NO3, 3.8%), 275
(C18H10ClN, 23.7%), 135 (C8H7O2, 100%). Anal. Calc. for:
(C20H16ClNO3) (M.W. = 353): C, 67.90; H, 4.56; N, 3.96%;
Found: C, 67.92; H, 4.56; N, 3.93%.
3.6. 2-Chloro-6-methoxy-3-[3-(4-methoxyphenyl)-4,5-dihydro-
1H-pyrazol-5-yl]quinoline (11)
A mixture of chalcone 10 (3.53 g, 10 mmole) and hydrazine
hydrate (1 ml, 20 mmole) was stirred in ethanol (20 ml) and
heated at reflux for 7 h. After completion of the reaction the
mixture was concentrated by evaporating out the solvent
under reduced pressure, and then poured onto ice water. The
obtained precipitate was filtered off, washed by water and
recrystallized from ethanol to afford compound 11 as white
needles. Yield: 60%; m.p. 114 C. IR (KBr) cm1: 3290
(NH), 3050 (CH aromatic), 2950 (CH aliphatic). 1H NMR
(DMSO-d6) d ppm: 8.4 (s, 1H, quinoline-H4), 7.8 (d, 1H,
J = 9.0 Hz, quinoline-H8), 8.6 (d, 2H, J = 9 Hz, phenyl-H2,
H6), 7.8 (s, 1H, NH, D2O-exchangeable), 7.5 (d, 1H,
J = 9 Hz, quinoline-H7), 7.4 (s, 1H, quinoline-H5), 7.1 (d,
2H, J = 9.0 Hz, phenyl-H3, H5), 5.1 (dd, 1H, J = 16.0,
9.2 Hz, pyrazole-H5), 3.8 (s, 3H, OCH3 of quinoline), 3.7 (s,
3H, OCH3 of phenyl), 3.6 (dd, 1H, J = 16.0, 9.2 Hz,
pyrazole-H4 axial proton), 2.9 (dd, 1H, J = 16.4, 9.2 Hz,
pyrazole-H4 equatorial proton). MS (m/z): 369 (C20H18ClN3-
O2, 15%, M+ 2), 367 (C20H18ClN3O2, 47.9%, M
+), 332
(C20H18N3O2, 10%) 200 (C12H12N2O, 27%), 175
(C10H11N2O, 100%). Anal. Calc. for: (C20H18ClN3O2) (M.
W. = 367): C, 65.30; H, 4.93; N, 11.42%; Found: C, 65.31;
H, 4.39; N, 11.43%.
3.7. General procedure for synthesis of 3-heteroaryl-2-chloro-6-
methoxyquinoline derivatives 12–17
A mixture of chalcone 10 (3.53 g, 10 mmole) and the appropri-
ate bi-nucleophile (10 mmole) was stirred in ethanol (20 ml),
and then sodium hydroxide (0.8 g, 20 mmole) was added.
The reaction mixture was heated under reflux for 7 h, and then
the solvent was evaporated under reduced pressure and poured
into ice water. The obtained precipitate was filtered off,
washed with copious amount of water and recrystallized from
ethanol to afford the corresponding 3-heteroaryl-2-chloro-6-
methoxyquinoline derivative 12–17.
3.7.1 5-(2-Chloro-6-methoxyquinolin-3-yl)-3-(4-
methoxyphenyl)-4,5-dihydroisoxazole (12)
Reddish solid. Yield: 65%; m.p. 140 C. IR (KBr) cm1: 3050
(CH aromatic), 2950 (CH aliphatic), 1590 (C‚N). 1H NMR
(DMSO-d6) d ppm: 8.3 (s, 1H, quinoline-H4), 7.8 (d, 1H,
J = 9.0 Hz, quinoline-H8), 7.7 (d, 2H, J = 9.0 Hz, phenyl-
H2, H6), 7.4 (s, 1H, quinoline-H5), 7.3 (d, 1H, J = 9.0 Hz,
quinoline-H7), 7.1 (d, 2H, J = 9.0 Hz, phenyl-H3, H5), 6.0
(dd, 1H, J = 14.0 Hz, isoxazole-H5), 4.0 (dd, 1H, J = 11,
5 Hz, isoxazole-H4 axial proton), 3.9 (s, 3H, quinoline
OCH3), 3.8 (s, 3H, phenyl OCH3), 2.9 (dd, 1H, J = 17,
4.8 Hz, isoxazole-H4 equatorial proton). MS (m/z): 370 (C20-
Table 1 Antifungal activities of compounds 7–17.
Comp. No. Chemical structure Tested fungi Inhibition zone (mm) Percent activity %
7
As. fumigatus 18.6 78.48
S. racemosum 14.8 75.13
G. candidum 14.3 49.83
C. albicans 0 0.00
8
As. fumigatus 16.3 68.78
S. racemosum 15.2 77.16
G. candidum 17.3 60.28
C. albicans 0 0.00
9
As. fumigatus 0 0.00
S. racemosum 0 0.00
G. candidum 0 0.00
C. albicans 0 0.00
10
As. fumigatus 15.7 66.24
S. racemosum 15.9 80.71
G. candidum 16.8 58.54
C. albicans 0 0.00
11
As. fumigatus 20.3 85.65
S. racemosum 21.6 109.64
G. candidum 23.4 81.53
C. albicans 0 0.00
12
As. fumigatus 20.4 86.08
S. racemosum 17.3 87.82
G. candidum 16.3 56.79
C. albicans 0 0.00
13
As. fumigatus 12.6 53.16
S. racemosum 13.6 69.04
G. candidum 15.2 52.96
C. albicans 0 0.00
14
As. fumigatus 16.3 68.78
S. racemosum 18.6 94.42
G. candidum 19.8 68.99
C. albicans 0 0.00
15
As. fumigatus 13.6 57.38
S. racemosum 16.8 85.28
G. candidum 16.5 57.49
C. albicans 0 0.00
16
As. fumigatus 20.3 85.65
S. racemosum 21.6 109.64
G. candidum 24.6 85.71
C. albicans 0 0.00
17
As. fumigatus 22.6 95.36
S. racemosum 21.4 108.63
G. candidum 20.8 72.47
C. albicans 0 0.00
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Table 1 (continued)
Comp. No. Chemical structure Tested fungi Inhibition zone (mm) Percent activity %
Amphotericin B* As. fumigatus 23.7 100.00
S. racemosum 19.7 100.00
G. candidum 28.7 100.00
C. albicans 25.4 100.00
* Amphotericin B was taken as standards for antifungal microbes.
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+),
230 (C12H7ClN2O, 19%), 219 (C12H10ClNO, 75%), 208
(C11H8N2O2, 33%), 135 (C8H7O2, 100%). Anal. Calc. for:
(C20H17ClN2O3) (M.W. = 368): C, 65.13; H, 4.65; N, 7.60%;
Found: C, 65.13; H, 4.67; N, 7.80%.
3.7.2. 6-(2-Chloro-6-methoxyquinolin-3-yl)-4-(4-
methoxyphenyl)pyrimidine-2 (1H)-thione (13)
Dark yellow solid. Yield: 40%; m.p. 150 C. IR (KBr) cm1:
3290 (NH), 3050 (CH aromatic), 2950 (CH aliphatic). 1H
NMR (DMSO-d6) d ppm: 12 (s, 1H, NH, D2O-exchangeable
proton), 8.5 (s, 1H, quinoline-H4), 8.3 (d, 1H, J = 15.0 Hz,
quinoline-H8), 8 (d, 2H, J = 9.0 Hz, phenyl-H2,H6), 7.7 (d,
1H, J = 15.0 Hz, quinoline-H7), 7.3 (s, 1H, quinoline-H5),
7.2 (s, 1H, pyrimidine-H5), 7.1 (d, 2H, J = 9.0 Hz, phenyl-
H3, H5), 3.9 (s, 3H, quinoline OCH3), 3.8 (s, 3H, phenyl
OCH3). MS (m/z): 411 (C21H16ClN3O2S, 0.15%, M+ 2),
409 (C21H16ClN3O2S, 0.5%, M
+), 202 (C11H5ClNO, 2.3%),
138 (C6H3N2S, 82%), 92 (C6H4O, 18%), 70 (C2HNS,
100%). Anal. Calc. for: (C21H16ClN3O 2S) (M.W. = 409): C,
61.53; H, 3.93; N, 10.25%; Found: C, 61.55; H, 3.96; N,
10.23%.
3.7.3. 4-(2-Chloro-6-methoxyquinolin-3-yl)-6-(4-
methoxyphenyl)pyrimidin-2-amine (14)
Yellow solid. Yield: 60%; m.p. 195 C. IR (KBr) cm1: 3300
(NH2), 3050 (CH aromatic-H’s), 2950 (CH aliphatic H’s).
1H
NMR (DMSO-d6) d ppm: 8.53 (s, 1H, quinoline-H4), 8.1 (d,
2H, J = 9.0 Hz, phenyl-H2,H6), 7.9 (d, 1H, J = 9.0 Hz,
quinoline-H8), 7.6 (s, 1H, pyrimidine-H5), 7.5 (d, 1H,
J = 9.0 Hz, quinoline-H7), 7.4 (s, 1H, quinoline-H5), 7 (d,
2H, J = 9.0 Hz, phenyl-H3, H5), 6.8 (s, 2H, NH2, D2O-
exchangeable protons), 3.9 (s, 3H, quinoline OCH3), 3.8 (s,
3H, phenyl OCH3). MS (m/z): 394 (C21H17ClN4O2, 1.3%,
M+ 2), 392 (C21H17ClN4O2, 4.15%, M
+), 200 (C11H10N3O,
16%) 175 (C9H9N3O, 33%), 133 (C8H7NO, 45%), 118
(C7H4NO, 60%), 77 (C4HN2,21H17ClN4O2) (M.W. = 392):
C, 64.21; H, 4.36; N, 14.26%; Found: C, 64.22; H, 4.37; N,
14.25%.
3.7.4. 6-(2-Chloro-6-methoxyquinolin-3-yl)-4-(4-
methoxyphenyl)pyrimidin-2 (1H)-one (15)
Light yellow solid. Yield: 60%; m.p. 180 C. IR (KBr) cm1:
3290 (NH), 3050 (CH aromatic), 2950 (CH aliphatic). 1H
NMR (DMSO-d6) d ppm: 11.9 (s, 1H, NH, D2O-
exchangeable proton), 8.52 (s, 1H, quinoline-H4), 8 (d,1H,
J = 15.0 Hz, quinoline-H8), 7.9 (d, 2H, J = 9.0 Hz, phenyl-
H2, H6), 7.74 (d, 1H, J = 15.0 Hz, quinoline-H7), 7.3 (s,
1H, quinoline-H5), 7.2 (s, 1H, pyrimidine-H5), 7.1 (d, 2H,
J = 9.0 Hz, phenyl-H3,H5), 3.9 (s, 3H, quinoline OCH3), 3.8(s, 3H, phenyl OCH3). MS (m/z): 395 (C21H16ClN3O3, 1.6%,
M+ 2), 393 (C21H16ClN3O3, 4%, M
+), 288 (C21H16ClN3O3,
4%, M+ 2), 229 (C21H16ClN3O3, 100%), 217 (C21H16ClN3-
O3, 2.85%). Anal. Calc. for: (C21H16ClN3O3) (M.W. = 393):
C, 64.05; H, 4.09; N, 10.67%; Found: C, 64.06; H, 4.11; N,
10.68%.
3.7.5. 3-[4-(2-Chloro-6-methoxyquinolin-3-yl)-6-(4-
methoxyphenyl)pyrimidin-2-yl]-1,1-dimethylguanidine (16)
Buff solid. Yield: 60%; m.p. 142 C. IR (KBr) cm1: 3290
(NH), 3050 (CH aromatic), 2950 (CH aliphatic). 1H NMR
(DMSO-d6) d ppm: 9.3 (s, 1H, NH, D2O exchangeable H),
8.5 (s, 1H, quinoline-H4), 8.3 (d, 2H, J = 9.0 Hz, phenyl-H2,
H6) 8.1 (d, 1H, J = 9.0 Hz, quinoline-H8), 7.6 (d, 1H,
J = 9.0 Hz, quinoline-H7), 7.3 (s, 1H, quinoline-H5), 7.2
(s,1H, pyrimidine-H5) 6.8 (d, 2H, J = 9.0 Hz, phenyl-H3,
H5), 5.6 (s, 1H, C‚NH, D2O exchangeable H), 3.9 (s, 3H,
quinoline OCH3), 3.8 (s, 3H, phenyl OCH3), 2.8 (s, 6H,
2CH3). Anal. Calc. for: (C24H23ClN6O2) (M.W. = 462): C,
62.27; H, 5.01; N, 18.15%; Found: C, 62.29; H, 5.03; N,
18.16%.
3.7.6. 2-Chloro-6-methoxy-3-(6-(4-methoxyphenyl)-2-
(methylthio)pyrimidin-4-yl)quinoline (17)
Brownish solid. Yield: 60%; m.p. 160 C. IR (KBr) cm1: 3050
(CH aromatic), 2950 (CH aliphatic). 1H NMR (DMSO-d6) d
ppm: 8.6 (s, 1H, quinoline-H4), 8.3 (d, 1H, J = 9.0 Hz,
quinoline-H8), 8 (d, 2H, J = 9.0 Hz, phenyl-H2,H6), 7.7 (d,
1H, J = 9.0 Hz, quinoline-H7), 7.3 (s, 1H, quinoline-H5), 7.2
(s, 1H, pyrimidine-H5), 7.1 (d, 2H, J = 9.0 Hz, phenyl-H3,
H5), 3.9 (s, 3H, quinoline OCH3), 3.8 (s, 3H, phenyl OCH3),
2.7 (s, 3H, SCH3). Anal. Calc. for: (C22H18ClN3O2S) (M.W.
= 423): C, 62.33; H, 4.28; N, 9.91%; Found: C, 62.34; H,
4.30; N, 9.93%.
3.8. Antimicrobial evaluation
All the newly synthesized compounds were screened for their
antifungal activity against Aspergillus fumigatus, Syncephalas-
trum racemosum, Geotriucum candidum and Candida albicans
by poisoned food technique.28 Bacterial and fungal strains
were procured from Regional Center for Mycology and
Biotechnology Laboratory, Cairo, Egypt. Ampicillin, Gentam-
icin and Amphotericin B were used as standards for antibacte-
rial and antifungal studies respectively. The inhibition zones of
bacteria were recorded after 24 h by visual observations while
that of fungi after 72–96 h of incubation. Results of antimicro-
bial studies and the activity percent for each compound com-
pared with the reference standard have been presented in
Tables 1 and 2 and Charts 1–3.
Table 2 Antibacterial activities of compounds 7–17.
Comp. No. Chemical structure Tested organism Inhibition zone (mm) Percent activity %
7
S. pneumoniae 14.5 ± 0.44 60.92%
Bacillus subtilis 14.9 ± 0.31 45.99%
P. aeruginosa 0 0.00
E. coli 15.6 73.24
8
S. pneumoniae 15.2 ± 0.44 63.87%
Bacillus subtilis 17.4 ± 0.25 53.7%
P. aeruginosa 0 0.00
E. coli 11.2 52.58
9
S. pneumoniae 0 0.00
Bacillus subtilis 0 0.00
P. aeruginosa 0 0.00
E. coli 0 0.00
10
S. pneumoniae 16.2 ± 0.15 68.07%
Bacillus subtilis 19.8 ± 0.42 61.11%
P. aeruginosa 0 0.00
E. coli 15.3 71.83
11
S. pneumoniae 20.6 ± 0.44 86.55%
Bacillus subtilis 23.4 ± 0.67 72.22%
P. aeruginosa 0 0.00
E. coli 18.6 87.32
12
S. pneumoniae 18.9 ± 0.44 79.41%
Bacillus subtilis 19.4 ± 0.53 59.88%
P. aeruginosa 0 0.00
E. coli 16.4 77.00
13
S. pneumoniae 14.6 ± 0.43 61.34%
Bacillus subtilis 16.2 ± 0.53 50%
P. aeruginosa 0 0.00
E. coli 13.7 64.32
14
S. pneumoniae 17.3 ± 0.63 72.69%
Bacillus subtilis 20.2 ± 0.44 62.35%
P. aeruginosa 0 0.00
E. coli 15.9 74.65
15
S. pneumoniae 16 ± 0.44 67.23%
Bacillus subtilis 18.3 ± 0.67 56.48%
P. aeruginosa 0 0.00
E. coli 13 61.03
16
S. pneumoniae 20.3 ± 0.44 85.29%
Bacillus subtilis 25.6 ± 0.63 79.01%
P. aeruginosa 0 0.00
E. coli 16.9 79.34
17
S. pneumoniae 21.9 ± 0.25 92.02%
Bacillus subtilis 22.3 ± 0.58 68.83%
P. aeruginosa 0 0.00
E. coli 23.9 112.21%
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Table 2 (continued)
Comp. No. Chemical structure Tested organism Inhibition zone (mm) Percent activity %
Ampicillin* S. pneumoniae 23.8 ± 0.2 100%
Bacillus subtilis 32.4 ± 0.58 100%
P. aeruginosa – –
E. coli – –
Gentamicin* S. pneumoniae – –
Bacillus subtilis – –
P. aeruginosa 17.3 ± 0.63 100%
E. coli 21.3 ± 0.58 100%
Screening procedure: The bacterial strain was uniformly spread using a sterile cotton swab on a sterile Petri dish MH agar. 1 mg/mL for each
test compound was added to wells (7 mm diameter holes cut in the agar gel, 20 mm apart from one another). The systems were incubated for
24 h at 36 C± 1 C, under aerobic conditions. After incubation, confluent bacterial growth was observed. Inhibition of the bacterial growth
was measured in mm and compared to that of reference compounds.
* Ampicellin and Gentamicin were taken as standards for anti Gram-positive and anti Gram-negative microbes respectively.
Chart 1 Antifungal activities of compounds 7–17.
Chart 2 Antimicrobial activities of compounds 7–17 against Gram-positive organisms.
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Chart 3 Antimicrobial activities of compounds 7–17 against Gram-negative organisms.
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From Tables 1 and 2 and Charts 1–3, it is clear that, the pyrim-
idine derivatives 16 and 17 showed the highest antimicrobial
activity against Gram-positive bacterial strains while the high-
est activity against E. coli as example of Gram-negative strains
was observed in the case of compounds 11 and 17 of which, 17
found more active than gentamicin. Almost all of synthesized
compounds gave moderate to low efficacy against B. subtilis
except compounds 11 and 16 which gave good activity with
72% and 76% relative to standard respectively. With the
exception of compound 9, all compounds showed promising
activities against three of the selected fungal strains of which,
compound 14 and 17 were found extremely potent. On the
other hand, no activity was found against either P. aeruginosa
or C. albicans by any of the tested compounds.
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